Agilent's (A) results for the fiscal fourth quarter reflect strong momentum in the pharma and applied markets. Also, robust demand across all end markets in China remained a positive.
By Peter Nurse
Agilent (A) delivered earnings and revenue surprises of 10.07% and 4.66%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?